# US 2015/0174203 A1 · Compositions And Methods For Modulating Pro-Inflammatory Immune Response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174203 A1
- Document ID: US20150174203A1
- Status: Published application
- Kind: A1
- Application number: 14/403,703
- Filed: 2013-05-30
- Published: 2015-06-25
- Earliest claimed: 2012-05-30
- Assignees: Icahn School of Medicine at Mount Sinai; Board of Regents, The University of Texas System
- Applicants: Icahn School of Medicine at Mount Sinai; The Board of Regents, The University of Texas System
- Inventors: Shu-Hsia Chen; Chengcheng Zhang; Xunlei Kang; Junke Zheng; Masato Umikawa
- Web page: https://patentgrep.com/patent/US20150174203A1

## CPC

- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 38/07: Tetrapeptides
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2803: {against the immunoglobulin superfamily}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/515: Angiogenesic factors; Angiogenin
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N 2800/7028: Cancer
- G01N 2800/7095: Inflammation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (LILR) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a LILR protein.

## Claims

### Claim 1

A composition comprising a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist and one or more additional agents selected from the group consisting of: a myeloid-derived suppressor cell, a mobilizing agent, a c-jun N-terminal kinase inhibitor, an anti-inflammatory agent, and an immunosuppressive agent.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is glatiramer acetate.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an angiopoietin-like (Angptl)-1 protein, an Angptl-2 protein, an Angplt-3 protein, an Angptl-4 protein, an Angptl-5 protein, an Angptl-6 protein, or an Angptl-7 protein.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, or Angptl-7 protein.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an Angptl-5 protein.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is formulated for intravenous, intramuscular, oral, subcutaneous, intraperitoneal, intrathecal, or intramuscular administration.

### Claim 7

A composition comprising:
one or more of an agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein; an oligonucleotide that decreases the expression of Angptl-1, Angptl-2, Angptl-3, Angptl-4, Angptl-5, Angptl-6, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 mRNA in a mammalian cell; and a soluble LILRB1 protein, soluble LILRB2 protein, soluble LILRB3 protein, soluble LILRB4 protein, or soluble LILRB5 protein; and
one or both of a chemotherapeutic agent and an analgesic.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 protein is an antibody or an antigen-binding antibody fragment.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the agent that specifically binds to Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 protein is an aptamer.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the oligonucleotide is an inhibitory RNA, an antisense RNA, or a ribozyme.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the inhibitory RNA is a small interfering RNA (siRNA).

### Claim 12 (depends on 7)

The composition of claim 7, wherein the composition is formulated for intravenous, intramuscular, oral, subcutaneous, intraperitoneal, intrathecal, or intramuscular administration.

### Claim 13

A method of decreasing a pro-inflammatory immune response in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist.

### Claim 14 (depends on 13)

The method of claim 13, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is glatiramer acetate.

### Claim 15 (depends on 13)

The method of claim 13, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an angiopoietin-like (Angptl)-1 protein, an Angptl-2 protein, an Angptl-3 protein, an Angptl-4 protein, an Angptl-5 protein, an Angptl-6 protein, or an Angptl-7 protein.

### Claim 16 (depends on 15)

The method of claim 15, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, or Angptl-7 protein.

### Claim 17 (depends on 15)

The method of claim 15, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an Angptl-5 protein.

### Claim 18 (depends on 13)

The method of claim 13, further comprising administering to the mammal one or more of a myeloid-derived suppressor cell, a mobilizing agent, a c-jun N-terminal kinase inhibitor, an anti-inflammatory agent, and an immunosuppressive agent.

### Claim 19 (depends on 13)

The method of claim 13, wherein the mammal is diagnosed as having inflammation, an autoimmune disease, or transplant rejection.

### Claim 20

A method of treating inflammation, an autoimmune disease, or transplant rejection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) agonist, a LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist.

### Claim 21 (depends on 20)

The method of claim 20, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is glatiramer acetate.

### Claim 22 (depends on 20)

The method of claim 20, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an angiopoietin-like (Angptl)-1 protein, an Angptl-2 protein, an Angptl-3 protein, an Angptl-4 protein, an Angptl-5 protein, an Angptl-6 protein, or an Angptl-7 protein.

### Claim 23 (depends on 22)

The method of claim 22, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, or Angptl-7 protein.

### Claim 24 (depends on 22)

The method of claim 22, wherein the LILRB1 agonist, LILRB2 agonist, LILRB3 agonist, LILRB4 agonist, or LILRB5 agonist is an Angptl-5 protein.

### Claim 25 (depends on 20)

The method of claim 20, further comprising administering to the mammal one or more of a myeloid-derived suppressor cell, a mobilizing agent, a c-jun N-terminal kinase inhibitor, an anti-inflammatory agent, and an immunosuppressive agent.

### Claim 26 (depends on 20)

The method of claim 20, wherein the mammal is diagnosed as having inflammation, an autoimmune disease, or transplant rejection.

### Claim 27 (depends on 20)

The method of claim 20, wherein the mammal is selected for organ or tissue transplantation.

### Claim 28

A method of stimulating a pro-inflammatory immune response in a mammal, the method comprising administering to the mammal a therapeutically effective amount of at least one of an agent that specifically binds to an endogenous angiopoietin-like (Angptl)-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein; an oligonucleotide that decreases the expression of Angptl-1, Angptl-2, Angptl-3, Angptl-4, Angptl-5, Angptl-6, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 mRNA in a mammalian cell; a soluble LILRB1 protein, a soluble LILRB2 protein, a soluble LILRB3 protein, a soluble LILRB4 protein, or a soluble LILRB5 protein.

### Claim 29 (depends on 28)

The method of claim 28, wherein the agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein is an antibody or an antigen-binding antibody fragment.

### Claim 30 (depends on 28)

The method of claim 28, wherein the agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein is an aptamer.

### Claim 31 (depends on 28)

The method of claim 28, wherein the oligonucleotide is an inhibitory RNA, an antisense RNA, or a ribozyme.

### Claim 32 (depends on 31)

The method of claim 31, wherein the inhibitory RNA is a small interfering RNA (siRNA).

### Claim 33 (depends on 28)

The method of claim 28, wherein the mammal is diagnosed as having a cancer.

### Claim 34 (depends on 28)

The method of claim 28, further comprising administering to the mammal a chemotherapeutic agent or an analgesic.

### Claim 35

A method of treating cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of at least one of: an agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein; an oligonucleotide that decreases the expression of Angptl-1, Angptl-2, Angptl-3, Angptl-4, Angptl-5, Angptl-6, Angptl-7, LILRB1, LILRB2, LILRB3, LILRB4, or LILRB5 mRNA in a mammalian cell; a soluble LILRB1 protein, a soluble LILRB2 protein, a soluble LILRB3 protein, a soluble LILRB4 protein, or a soluble LILRB5 protein.

### Claim 36 (depends on 35)

The method of claim 35, wherein the agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein is an antibody or an antigen-binding antibody fragment.

### Claim 37 (depends on 35)

The method of claim 35, wherein the agent that specifically binds to an endogenous Angptl-1 protein, Angptl-2 protein, Angptl-3 protein, Angptl-4 protein, Angptl-5 protein, Angptl-6 protein, Angptl-7 protein, LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, or LILRB5 protein is an aptamer.

### Claim 38 (depends on 35)

The method of claim 35, wherein the oligonucleotide is an inhibitory RNA, an antisense RNA, or a ribozyme.

### Claim 39 (depends on 39)

The method of claim 39, wherein the inhibitory RNA is a small interfering RNA (siRNA).

### Claim 40 (depends on 35)

The method of claim 35, wherein the mammal is diagnosed as having a cancer.

### Claim 41 (depends on 35)

The method of claim 35, further comprising administering to the mammal a chemotherapeutic agent or an analgesic.

### Claim 42

A method of identifying a candidate agent for treating an autoimmune disease, inflammation, or transplant rejection in a mammal, the method comprising:
(a) contacting a leukocyte immunoglobulin-like receptor (LILR) B1 (LILRB1) protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or a paired immunoglobulin-like receptor B (PIRB) protein with a test agent, and determining the amount of binding of the test agent to the LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein;
(b) determining whether the test agent activates LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein signaling in a cell; and
(c) selecting a test agent that binds to LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein, and activates LILRB1 protein, LILRB2 protein, LILRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein signaling in a cell, respectively, as a candidate agent for treating an autoimmune disease, inflammation, or transplant rejection in a mammal.

### Claim 43 (depends on 42)

The method of claim 42, wherein the LILRB1 protein, LILRB2 protein, LLRB3 protein, LILRB4 protein, LILRB5 protein, or PIRB protein in (a) is expressed on the surface of a cell.

### Claim 44 (depends on 42)

The method of claim 42, wherein the cell in (b) is a T-cell.

### Claim 45 (depends on 43)

The method of claim 43, wherein the cell is in (b) a myeloid-derived suppressor cell.

### Claim 46

A method of identifying a candidate agent useful for treating a cancer in a mammal, the method comprising:
contacting an angiopoietin-like (Angptl)-1 protein, an Angptl-2 protein, an Angptl-3 protein, an Angptl-4 protein, an Angptl-5 protein, an Angptl-6 protein, or an Angptl-7 protein with a test agent;
determining whether the test agent binds to the Angptl-1 protein, the Angptl-2 protein, the Angptl-3 protein, the Angptl-4 protein, the Angptl-5 protein, the Angptl-6 protein, or the Angptl-7 protein; and
selecting a test agent that specifically binds to the Angptl-1 protein, the Angptl-2 protein, the Angptl-3 protein, the Angplt-4 protein, the Angptl-5 protein, the Angptl-6 protein, or the Angptl-7 protein as a candidate agent for treating a cancer in a mammal.
